Respiratory diseases pose a huge healthcare burden worldwide and contribute significantly to premature mortality. At Evotec, we possess extensive expertise in various respiratory diseases and pathologies such as asthma, IPF, COPD, airway inflammation, and infection. Our well-established and continuously expanding respiratory disease capabilities are supported by a dedicated team of respiratory scientists, with experience in range of modalities, routes of administration and target classes, including GPCRs, ion channels, transporters, and enzymes.

We have extensive experience in running in vitro models of disease pathophysiology, precision cut lung slice technology, in vivo studies of clinically relevant measures of lung function (flexivent) and translational biomarkers. This is all supported with our ADME/DMPK expertise in both systemic and lung delivery of potential new therapeutics, which enables fast efficient progress of drug discovery programs from target ID to IND-enabling studies.